Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microplegia is an undiluted blood cardioplegia technique used for myocardial protection during cardiac surgery, such as aortic or mitral valve replacement. Developed as an alternative to standard 4:1 diluted blood cardioplegia, microplegia utilizes the patient's own oxygenated blood as the primary vehicle, supplemented with concentrated additives like potassium chloride and magnesium sulfate. This approach is designed to stop the heart (cardioplegia) while providing optimal oxygen delivery and minimizing the systemic hemodilution associated with crystalloid-heavy solutions. Washington University School of Medicine has investigated this strategy in Phase 4 trials to determine its efficacy in reducing perioperative red blood cell transfusion requirements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microplegia.